Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BulgariaBack to Bulgaria

Clinical trials in Kazanlak

17 clinical trials in Kazanlak, Bulgaria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kazanlak at a glance
17
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

17 trials in Kazanlak

Open in trial search

Schizophrenia

Recruiting

Study of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Evenamide
  • Sponsor:Newron Pharmaceuticals S.p.A.

Schizophrenia

Recruiting

Study on Vafidemstat for Treating Negative Symptoms and Cognitive Impairment in Adults with Schizophrenia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vafidemstat
  • Sponsor:Oryzon Genomics S.A.

Dermatitis atopic

Recruiting

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Schizophrenia

Recruiting

A study to assess the safety and effectiveness of GXV813 in hospitalized adults with schizophrenia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:GXV813
  • Sponsor:Novartis Pharma AG

Schizophrenia

Recruiting

A study to evaluate the effectiveness and safety of NBI-1117570 in adults with schizophrenia who require hospital treatment.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:HTL0022537
  • Sponsor:Neurocrine Biosciences Inc.

Major depression

Recruiting

A study to evaluate the effectiveness and safety of DT-101 in adults with major depressive disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Draig Therapeutics Limited

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bipolar I disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) for treatment of manic episodes in adults with bipolar I disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Major depression

Not yet recruiting

Evaluation of Trazodone Hydrochloride for Improving Emotional Blunting in Patients with Major Depressive Disorder

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Trazodone hydrochloride
  • Sponsor:Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A.

Bipolar I disorder

Not yet recruiting

A study to evaluate the safety and effectiveness of azetukalner in patients with bipolar depression

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Bipolar I disorder

Not yet recruiting

A study to evaluate the effectiveness and safety of azetukalner in patients experiencing depressive episodes associated with bipolar disorder.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Kazanlak

What the registry says about research in the country

01 Psychiatric Disorders Research

Innovative clinical trials focusing on schizophrenia treatment, testing new adjunctive therapies to help patients with inadequately controlled symptoms. Multiple studies are evaluating novel compounds to enhance the effectiveness of existing treatments.

  • Treatment-resistant schizophrenia
  • Adjunctive therapy development
  • Long-term safety assessment

Research aims to improve quality of life for patients with persistent symptoms.

02 Mood Disorders Studies

Groundbreaking research into bipolar I disorder, specifically focusing on manic episodes and mixed features. Studies are evaluating new therapeutic approaches for acute treatment of mania.

  • Bipolar mania management
  • Mixed episode treatment
  • Acute intervention strategies

Trials aim to establish effective interventions for acute manic episodes.

03 Depression Research

Advanced clinical investigations targeting Major Depressive Disorder with innovative approaches. Studies are exploring genetic factors and new pharmaceutical interventions for improving depressive symptoms.

  • Targeted therapy development
  • Genetic profile assessment
  • Symptom improvement evaluation

Research focuses on personalized treatment approaches based on genetic markers.

Back to BulgariaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.